Drug Update · Rare Disease

FDA Approves navepegritide for Achondroplasia: 1.5 cm Growth Gain

July 11, 2026

Approval date

2026-02-27

Indication

Increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses

Primary endpoint difference

1.5 cm/year (AGV benefit vs placebo at 52 weeks)

Pivotal trial

APPROACH (randomized, double-blind, placebo-controlled; NCT05598320)

Clinical Perspective

Pediatric endocrinologists and other clinicians caring for children with achondroplasia (patients aged 2 years and older with open epiphyses) are the primary audience for this approval. The randomized, placebo-controlled data support that once-weekly navepegritide increases linear growth, with an AGV improvement of 1.5 cm/year versus placebo over 52 weeks. Will ongoing confirmatory studies verify a clinically meaningful improvement in final adult height and related long-term outcomes?

Editorial Team · Rare Disease

The U.S. Food and Drug Administration approved Yuviwel (navepegritide) for injection to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses on 2026-02-27. Approval was granted under accelerated approval based on the APPROACH randomized clinical trial showing an annualized growth velocity benefit of 1.5 cm over 52 weeks versus placebo ^[4]^[5].

Clinical Context

Navepegritide (brand: YUVIWEL) is a C-type natriuretic peptide (CNP) analog and a prodrug that releases active CNP, developed by Ascendis Pharma Endocrinology, Inc. The CNP moiety binds natriuretic peptide receptor-B (NPR-B) and inhibits MAPK signaling implicated in achondroplasia pathophysiology, thereby promoting chondrocyte differentiation and proliferation and stimulating endochondral bone growth ^[2]^[3]^[5]. The FDA granted priority review and accelerated approval for the indication to increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses, with continued approval contingent on verification of clinical benefit in confirmatory trial(s) ^[3]^[5].

Key Findings

The APPROACH randomized, double-blind, placebo-controlled trial demonstrated that once-weekly navepegritide produced an improvement in annualized growth velocity (AGV). The trial reported a least-squares mean treatment difference of 1.49 cm/year (95% CI, 1.05 to 1.93; P < .001) versus placebo in the publication of the trial ^[1]. The FDA and prescribing information summarize this as a 1.5 cm greater growth over 52 weeks versus placebo ^[4]^[5].
In APPROACH, additional skeletal and functional outcomes favored navepegritide, with reported least-squares mean treatment differences of tibial-femoral angle -1.81° (95% CI, -3.16 to -0.47), mechanical axis deviation -2.78 mm (95% CI, -4.71 to -0.86), fibula-to-tibia length ratio -0.016 (95% CI, -0.024 to -0.008), and improvement in Achondroplasia Child Experience Measures–Physical Functioning of -11.1 (95% CI, -21.5 to -0.80) in children younger than 5 years ^[1]^[5].
Trial enrollment and randomization: 84 pediatric participants were randomized 2:1 to navepegritide (n = 57) or placebo (n = 27) and analyzed for efficacy and safety through 52 weeks; an open-label extension is ongoing, and maintenance of AGV with longer treatment was reported in extension data ^[1]^[5].

Safety & Tolerability

Vomiting (most common adverse reaction) ^[3].
Injection-site reaction (including swelling, erythema, bruising, pruritus, pain, discoloration, hemorrhage, vesicles, edema) ^[3].
Pain in extremity ^[3].
Nausea ^[3].
Hypertrichosis (reported in trials as localized or generalized increased body hair growth) ^[3].
Transient low blood pressure has been reported with a once-daily CNP analog and is noted as a warning in the prescribing information; patients should contact their health care provider if they experience symptoms of decreased blood pressure such as dizziness, fatigue, or nausea ^[2]^[3].
No serious adverse events were judged treatment-related in the APPROACH publication, and no deaths occurred; injection-site reaction rates were described as low, and no symptomatic hypotension or fractures were observed in the published trial report ^[1].

Study Design

The FDA approval was supported by Trial 1 (APPROACH), a phase 2b randomized, double-blind, placebo-controlled trial with a 52-week blinded treatment period followed by an open-label extension; enrollment occurred March–August 2023 across 10 hospitals internationally. Eligible participants were treatment-naive children aged 2 to 11 years with genetically confirmed achondroplasia; 84 participants were randomized 2:1 to once-weekly subcutaneous navepegritide or placebo and all randomized participants were included in efficacy and safety analyses ^[1]^[5]. The primary endpoint was annualized growth velocity at Week 52 ^[1]^[5].

FAQ

Q1 What is Yuviwel (navepegritide) approved for?

YUVIWEL (navepegritide) is approved to increase linear growth in pediatric patients 2 years of age and older with achondroplasia who have open epiphyses. The approval is an accelerated approval based on an improvement in annualized growth velocity observed over 52 weeks; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Q2 How does navepegritide work?

Navepegritide is a prodrug that releases C-type natriuretic peptide (CNP). CNP binds natriuretic peptide receptor-B (NPR-B), which inhibits the MAPK signaling pathway that is overactive in achondroplasia due to FGFR3 gain-of-function. By increasing cGMP and signaling through protein kinase G, CNP antagonizes overactive FGFR3 signaling, promoting chondrocyte differentiation and proliferation and stimulating endochondral bone growth.

Q3 What is the recommended dose of Yuviwel?

YUVIWEL is administered once-weekly by subcutaneous injection with weight-based dosing. The prescribing information provides a recommended weekly dosage table (for example, 8 to 9.9 kg: 0.88 mg; 10 to 13.4 kg: 1.2 mg; 13.5 to 17.5 kg: 1.6 mg; up to 73.6 to 90 kg: 8.8 mg using 2 Kits where applicable). Dosage should be adjusted periodically according to body weight and discontinued upon epiphyseal closure. Clinicians should consult current prescribing information for full dosing guidance.

Q4 What are the most common side effects?

The most common adverse reactions reported (≥ 5%) include vomiting, injection-site reactions, pain in extremity, and nausea. Hypertrichosis was observed in a small number of trial participants. Transient decreases in blood pressure have been reported with a once-daily CNP analog and are noted as a risk in the prescribing information; patients with symptoms of low blood pressure should contact their health care provider. No treatment-related serious adverse events or deaths were reported in the pivotal trial.

Clinicians should consult current prescribing information for full dosing guidance.

FDA Approves navepegritide for Achondroplasia: 1.5 cm Growth Gain

FDA Approves navepegritide for Achondroplasia: 1.5 cm Growth Gain

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Rare Disease in your inbox.

Related Clinical Updates

FDA Approves marnetegragene autotemcel for LAD-I: 100% HSCT-free

FDA Approves Elamipretide for Barth Syndrome: 63 N Knee Strength Gain

FDA Approves KYGEVVI for TK2d: Cuts Death Risk 86%

Verified HCP Portal